Chronic lymphocytic leukemia (CLL) remains the most common leukemia of adults and is incurable. Several novel therapies are substantially altering the treatment landscape for CLL however, and studying mechanisms of resistance to these therapies is of great interest. Our lab focuses on CLL and the genomics of CLL with several particular interests, one of which is identifying mechanisms of resistance to novel therapies, especially kinase inhibitors, as well as identifying next generation drugs that can be effective in resistant patients.
Located in Boston and the surrounding communities, Dana-Farber Cancer Institute brings together world renowned clinicians, innovative researchers and dedicated professionals, allies in the common mission of conquering cancer, HIV/AIDS and related diseases. Combining extremely talented people with the best technologies in a genuinely positive environment, we provide compassionate and comprehensive care to patients of all ages; we conduct research that advances treatment; we educate tomorrow's physician/researchers; we reach out to underserved members of our community; and we work with amazing partners, including other Harvard Medical School-affiliated hospitals.
The ideal candidate for this post-doctoral fellowship will have familiarity and experience working with primary cells in cell culture and performing a variety of molecular and cellular biology experiments including assays to assess the activity of novel drugs and their mechanism of action in these cells.
Previous experience in molecular biology is required. This position will focus on the analysis of signaling mechanisms in lymphocytes and evaluation of the impact of novel drug candidates. MD, PhD or MD/PhD is required.
Dana-Farber Cancer Institute is an equal opportunity employer and affirms the right of every qualified applicant to receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.